Company Overview and News
Boston Scientific Corporation's (BSX - Free Report) MedSurg business group (comprising three sub segments viz. Endoscopy, Urology and Pelvic Health and Neuromodulation) has been recording operational sales growth over the last few quarters. We expect this upside to further find reflection in first-quarter 2018 results, scheduled for release on Apr 25.
MOUNTAIN VIEW, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the appointment of Maria Sainz and David Bruce to the Company’s Board of Directors effective as of April 13, 2018. Ms. Sainz and Mr. Bruce will both join the Compensation Committee. Ms. Sainz will also join the Nominating and Governance Committee. Concurrent with these additions, George Marcellino will depart from the Board of Directors to focus on his new role as IRIDEX’s Vice President of Clinical Affairs.
For long-term investors, the recent market hiccups and volatility has opened up some pretty big bargains. And some of the biggest can be found in the among the various healthcare stocks. From medical device firms to small biotech stocks, the healthcare sector has been hit hard over the last few weeks.
HINGHAM, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the appointment of Mr. Simon Sharon as Chief Technology Officer, effective immediately. In his role, Mr. Sharon will report directly to Harel Gadot, Microbot’s Chief Executive Officer, President and Chairman, and resume the role previously held by the VP of R&D, who recently stepped down to pursue other endeavors.
On April 3, 2018, Boston Scientific (BSX) announced the acquisition of Ohio-based Securus Medical for an upfront cash payment of $40 million. The deal also includes commercial milestones and regulatory achievement–based contingent payments of up to $10 million. Boston Scientific, which invested in Securus for the first time in 2016, already has a stake in the company. The specified payments are for the remaining stake in the company not already owned by Boston Scientific.
Boston Scientific Corporation (BSX - Free Report) recently announced the acquisition of Securus Medical Group, Inc — a privately-held developer of thermal monitoring system for the continuous measurement of esophageal temperature. The buyout is in line with the company’s strategy to gain traction in the global Electrophysiology (EP) market, which is poised to reach a value of around $4.73 billion by 2019 (per data by Markets and Markets).
Edwards Lifesciences (EW) is a leading player in the TAVR (transcatheter aortic valve replacement) market. The company registered strong fiscal 2017 results on February 1, 2018, despite being impacted by natural disasters during the year. The company manufactures Sapien valves. In this article, let’s take a look at Wall Street’s ratings, recommendations, and 12-month target prices for EW stock.
In 1Q18, Varian Medical Systems (VAR) reported revenues of $679 million, which is a YoY (year-over-year) rise of 13% on a reported basis and an 11% rise on a constant currency basis. It was mainly driven by increased sales of its linac (linear accelerator) systems in the oncology operating segment. The company’s product sales were $366 million, which is an 18% YoY growth. Services accounted for the remaining $313 million of revenues in 1Q18, which was a YoY rise of 7%.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET